



Kennedy Krieger Institute Tuberous Sclerosis Clinic

## The TREATMENT Trial

### Topical Rapamycin to Erase Facial Angiofibromas in TSC— Multicenter Evaluation of a Novel Therapy

#### **What is the goal of the research study?**

To determine if a topical rapamycin cream can reduce the appearance of facial angiofibromas in patients with Tuberous Sclerosis Complex (TSC) when compared to placebo.

#### **Who can participate?**

TSC patients of all ages with visible facial angiofibromas.

#### **What does the treatment consist of?**

Applying study cream to the affected areas of the face nightly for 6 months.

#### **What do I have to do and for how long?**

The study requires 7 visits in 6 months to the study clinic. Study participants must be able to cooperate with blood draws, photography and applying the study drug. Pregnant or nursing females are not able to participate. Patients that are already taking rapamycin, affinitor, or other immunosuppressive drugs are not eligible.

#### **Will it cost me anything?**

You will be provided with study cream at no cost to you for the 6 months that you are in the study. The study procedures and lab results will not be charged to you. Your parking will be covered if you park at the Kennedy Krieger Institute garage off of Ashland Drive. You will be responsible for any other expenses associated with your participation, such as travel and meal costs.

Interested individuals can direct questions to the Study Coordinator at 443-923-7619, or email [ResearchTrials@kennedykrieger.org](mailto:ResearchTrials@kennedykrieger.org).

Principal Investigator: Tanjala T. Gipson, M.D.

IRB study no: NA\_00083442

Clinicaltrials.gov ID: NCT01526356



Approved August 27, 2013